FeesSafety
Pluang+
Home/Explore/US Market Price/Stocks/BIIB
icon
Up to 4x
Us company
Asset icon - trade crypto, stocks, and gold on Pluang

Biogen Inc (BIIB) Stock Price Today

TechnicalsFundamentalsFinancialsNewsCorp ActionAboutCompare
24H
1W
1M
3M
YTD
1Y
5Y

Aura AI Summary

Biogen (BIIB) trades at $252.65, up 0.78% with strong technical momentum as the stock approaches resistance near $254. The company has demonstrated consistent earnings beats in recent quarters with Q2 2026 EPS of $3.60 exceeding expectations by 22%. Recent positive clinical trial results for litifilimab in cutaneous lupus and regulatory approvals for LEQEMBI in Japan and China highlight pipeline progress. Valuation metrics show a P/E of 44.81 and P/S of 3.72, reflecting premium pricing relative to historical levels.
Biogen presents a mixed investment case with strong analyst support (65% buy ratings) but elevated valuation concerns. The company's strategic expansion beyond neuroscience into immunology and kidney disease offers growth potential, though declining net income margins from 16.86% in 2024 to 8.32% projected for 2026 warrant monitoring. Key risks include pipeline execution and competitive pressures in the Alzheimer's drug market. The current price sits above the consensus target of $245.63, suggesting near-term consolidation potential.
Read full analysis

Key Stats

  • Market Cap
    $37.27B
  • Volume
    958,816
  • Sector
    Health
  • 52W High
    $253.84
  • 52W Low
    $147.86
  • Typical Hold Time
    111 Days
  • Enterprise Value
    $44.34B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$252.64
52W Low: $147.86
29 Oct 2025
52W High: $253.84
22 Oct 2026

Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $147.86 and a high of $253.84, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

About Biogen Inc

Biogen and Idec merged in 2003, combining forces to market Biogen's multiple sclerosis drug Avonex and Idec's cancer drug Rituxan. Today, Rituxan and next-generation antibody Gazyva are marketed via a collaboration with Roche. Biogen also markets novel MS drugs Plegridy, Tysabri, Tecfidera, and Vumerity. In Japan, Biogen's MS portfolio is co-promoted by Eisai. Hemophilia therapies Eloctate and Alprolix (partnered with SOBI) were spun off as part of Bioverativ in 2017. Biogen has several drug candidates in phase 3 trials in neurology and neurodegenerative diseases and has launched Spinraza with partner Ionis. Aduhelm was approved as the firm's first Alzheimer's disease therapy in June 2021.

Most Recent News

Content is generated by Aura AI

Bitget Wallet launches free USD and EUR virtual accounts for 100M users, enabling easy stablecoin access and cross-border payments.

Bitget Wallet introduced Virtual Account, allowing users to open free USD and EUR accounts within their self-custodial crypto wallet, powered by licensed partner Noah. Funds deposited convert automatically to stablecoins like USDT or USDC, usable for...

Market News
3 hours ago
Na
Bullish
news icon
Bitget Wallet launches free USD and EUR virtual accounts for 100M users, enabling easy stablecoin access and cross-border payments.

KBC Group's capital remains well above ECB minimum requirements in 2026 SREP review.

The European Central Bank (ECB) has confirmed KBC Group's minimum capital requirements for 2026 following its Supervisory Review and Evaluation Process (SREP). KBC must maintain a fully loaded CET1 ratio of 10.94%, which includes various regulatory b...

Market News
3 hours ago
Na
Bullish
news icon
KBC Group's capital remains well above ECB minimum requirements in 2026 SREP review.

KBC's capital remains well above ECB's minimum requirements for 2026 at 14.4% CET1 ratio.

The European Central Bank (ECB) has confirmed KBC Group's minimum capital requirements for 2026, maintaining the Pillar 2 Requirement at 1.95% and Pillar 2 Guidance at 1.00%. This results in an overall CET1 capital requirement of 10.94%. As of Q2 202...

Market News
3 hours ago
Kbc Group
Bullish
news icon
KBC's capital remains well above ECB's minimum requirements for 2026 at 14.4% CET1 ratio.
Catch up fast with Aura AI
Get an AI-generated news summary for this asset in seconds.

People also bought

Frequently Asked Questions

US stocks trading hours: Monday - Friday (Except for US public holidays) Time: 21.30 - 04.00 WIB 20.30 - 03.00 WIB (Daylight Savings Time*) *The next Daylight Savings is scheduled to begin on March 13, 2022 and ends on November 6, 2022. You can place limit orders outside of the trading hours, but it can only be executed during trading hours. For illustration, a stock is currently trading at $10 per share, but you only want to pay $7 per share at most. Let’s say you set your limit price to $7 at 18.00. Your order will be executed when the market is open at 21.30 if the stock drops from $10 to $7 or lower. Similarly, if the stock price doesn’t drop to $7, your order won’t be executed.
Yes, you are eligible to receive dividend payment if and when the company pays them on one condition: minimum net dividend paid is at least $0.01. Net dividend is gross dividend subtracted by 15% withholding tax.
Yes, it is. US Stocks risk is managed by PT PG Berjangka which is licensed by Badan Pengawas Perdagangan Berjangka Komoditi (BAPPEBTI), and your investment is guaranteed by Jakarta Futures Exchange (JFX) and Indonesian Clearing House (KBI).
Pluang charges a fixed transaction fee of 0.30% for regular users and 0.20% for Pluang Plus members, including VAT to cover the exchange fees and operational costs.
US Stocks, ETFs, and Options are facilitated by PT PG Berjangka in its capacity as a Licensed Derivatives Broker supervised by the Financial Services Authority of Indonesia (OJK) for financial derivative products with underlying securities. All transactions are recorded on the Jakarta Futures Exchange (JFX) and the Indonesian Futures Clearing House (KBI). In addition, PT PG Berjangka is also a Licensed Futures Broker supervised by the Commodity Futures Trading Regulatory Agency (Bappebti). Read our product’s Terms and Conditions

All investments involve risks and the possibility of a loss in investment value. Past performance is not indicative of future results. Historical performance, expected returns, and probability projections are provided for informational and illustrative purposes only.

Key Stats

  • Market Cap
    $37.27B
  • Volume
    958,816
  • Sector
    Health
  • 52W High
    $253.84
  • 52W Low
    $147.86
  • Typical Hold Time
    111 Days
  • Enterprise Value
    $44.34B
  • Div Yield
    -
  • Trading Activity
    0% Sell | 100% Buy
$252.64
52W Low: $147.86
29 Oct 2025
52W High: $253.84
22 Oct 2026

Track Biogen Inc (BIIB) stock price today on Pluang, updated in real time with live charts and market data. Over the past 52 weeks, Biogen Inc has traded between a low of $147.86 and a high of $253.84, highlighting its annual price range. Buy and sell Biogen Inc shares on Pluang with fractional shares and real-time market data — safe and OJK-regulated.

Let’s invest in this asset by signing up or download!